Pharmacists in Minonk, IL Accepting Medicare
7 Pharmacists found. Showing 1 - 7
 Dr. Neil Paul Heineke, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 568 N Chestnut St, Minonk, IL 61760 Phone: 309-432-3451 Fax: 309-432-2575 |
Joseph Lutterbie, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1305 N Carolyn Dr, Minonk, IL 61760 Phone: 309-432-3421 Fax: 800-475-2575 |
David D Wegman, RPH, MS, FASCP, CGP Pharmacist - Geriatric Medicare: Not Enrolled in Medicare Practice Location: 568 N Chestnut St, Minonk, IL 61760 Phone: 309-432-3451 Fax: 309-432-3625 |
 Jamie Harrison, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1305 N Carolyn Dr, Minonk, IL 61760 Phone: 309-432-3451 |
Stephanie M Bressner, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1305 N Carolyn Dr, Minonk, IL 61760 Phone: 309-432-3451 |
Jeremy Gray, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1305 N Carolyn Dr, Minonk, IL 61760 Phone: 309-432-3451 |
Randall Stuerman, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1305 N Carolyn Dr, Minonk, IL 61760 Phone: 309-432-3451 |
News Archive
Novel, highly specific treatment method for hyperinsulinemic hypoglycemia
A new method to treat hyperinsulinemic hypoglycemia has proven highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of the Journal of Nuclear Medicine.
NanoString announces Early Access Program for nCounter Elements used in translational research
NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an Early Access Program for nCounter Elements™, a line of General Purpose Reagents (GPRs) developed specifically to meet the needs of translational research and clinical laboratories.
Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.
Groundbreaking ceremony for Ravensburg Vetter West facility
A groundbreaking ceremony was held today for Vetter's newest facility, Ravensburg Vetter West. Vetter, a specialist in aseptically pre-filled drug-delivery systems, will build a state-of-the-art high bay warehouse for cold-storage and room-temperature goods. Space will also be dedicated for automatic and manual visual inspection as well as for stability chambers designed to the highest standards.
› Verified 4 days ago